NCT06526364Recruiting
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
Clinnova-MS: a Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-Regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care (Switzerland)
Source: ClinicalTrials.gov · Last updated 26 Dec 2025
Brief summary (registry, in English)
This prospective cohort study is part of the Clinnova programme and aims to (i) identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and with transitioning phases to progressive MS, as well as (ii) to investigate digital biomarkers allowing the continuous clinical monitoring of those patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 18 Jul 2024
- Start date
- 10 Dec 2024
- Primary completion date
- Jun 2029
- Lead sponsor
- University Hospital, Basel, Switzerland
- Diseases
- Multiple sclerosis
- NCT number
- NCT06526364
What you commit to
- Study type: Observational
- Planned participants: 100
- From 10 Dec 2024 to the primary completion date, Jun 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Age ≥18
- Participants are willing and able to comply with the protocol, including undergoing data and samples collection as well as study visits and examinations.
- Signed informed consent form
- In possession of a Healios+Me app compatible smartphone (iOS/Android)
- Corrected close visual acuity of ≥0.5
- Hand motor skills sufficient for using a smartphone
- Ability to follow the study procedures
- Diagnosed with MS according to the revised McDonald criteria 2017, all clinical forms inclusive (clinically isolated syndrome, RRMS, SPMS, PPMS) AND early disease stages (\< 3 years) OR transitioning phase to progressive disease as evaluated based on Expanded Disability Status Scale (EDSS).
- Enrolled in the SMSC at University Hospital Basel
- There are no specific exclusion criteria.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) Coordinator of this site? Confirm its status | Basel | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.